METTLER TOLEDO INTERNATIONAL INC/ (MTD) Company Report

Mettler-Toledo generated $4 billion in revenue, with the majority of sales in #1 global market-share segments—over 70% in pharma/biopharma, food manufacturing, specialty chemicals, and low-double-digit exposure to bioprocessing.
Key growth engines include the Spinnaker 6 digital sales program, SternDrive pricing initiative, Blue Ocean global IT/supply-chain harmonization, and Jetstream innovation framework to drive share gains and automation/digitalization.
The service business accounts for ~25% of sales, underpinned by a $3 billion serviceable installed base; Mettler-Toledo aims to outpace company-wide growth through expanded coverage, targeted campaigns, and channel-partner acquisitions.
Medium-term financial targets call for ≥6% annual sales growth, 100 bps of margin expansion, ≈100% net-income conversion to free cash flow, and mid-teens EPS growth via share repurchases.
For 2026, the company guides ≈4% revenue growth (≈2.5% pricing, ≈1% organic volume, acquisition lift), expecting market stabilization and upside from onshoring/reshoring trends.

1 day ago

Transcript

Mettler-Toledo outlines strategy at J.P. Morgan Healthcare Conference

MTD

Guidance Update

Mettler-Toledo is a global leader in precision instruments with ~$4 billion in annual revenue, holding #1 market share in the majority of its segments; its portfolio comprises 56% laboratory instruments and 40% industrial products.
The company focuses on high-value end markets—pharma/biopharma, food manufacturing, and specialty chemicals account for >70% of sales—with 16% of revenue from China and 17% from other emerging markets.
Key growth drivers include the Spinnaker sales-and-marketing program (Wave 6 launched in 2024), the Jetstream innovation framework, and a service business that represents 25% of sales with a $3 billion serviceable market (currently one-third covered).
Financial targets include ≥6% annual sales growth, ≥100 bps of margin expansion, converting ~100% of net income into free cash flow, and mid-teens EPS growth via share repurchases.
The firm is mitigating a 6% EPS tariff headwind in 2026 (vs. 5% in 2025) with full offsets planned; key U.S. import exposures are now $30 million from China, >$100 million from Mexico, and <$100 million from Switzerland—any tariff refunds would be passed through to customers.

1 day ago

Transcript

Mettler-Toledo outlines growth strategy and 2026 guidance at J.P. Morgan Healthcare Conference

MTD

Guidance Update

Mettler-Toledo reported about $4 billion in revenue, leading market positions in precision instruments, with 60 % of sales in high-growth end markets such as pharma, food manufacturing, and specialty chemicals, and a presence in 140 countries.
The company’s Spinnaker 6 program (launched in 2024) advances digitalization and big-data analytics—including the Top K lead-generation tool—and its Jetstream innovation process targets rapid new-product development; service represents 25 % of sales with a $3 billion addressable installed-base opportunity.
Targets 100 basis points of annual margin expansion driven by 6 %+ organic sales growth, SternDrive global pricing, Blue Ocean IT integration, and supply-chain optimization (in-region manufacturing for flexibility).
Guides 4 % sales growth in 2026, expecting replacement cycles to normalize and potential upside; tariff headwinds to EPS cut from 6 % to 4 % after a U.S.-Switzerland trade deal—full mitigation planned, with reclamation efforts if required—supported by an agile global supply chain.

1 day ago

Transcript

Mettler Toledo presents end-market diversification, growth initiatives, and 2024 financial performance

MTD

Diversified sales mix: Life Sciences ~40%, Food Manufacturing ~20%, Chemical ~13%, Other ~28% of total sales.
Geographic distribution: Americas 42%, Europe 29%, Asia/ROW 29%; emerging markets represent ~33% of sales.
Innovation and digitalization focus: Launch of Spinnaker 6 program leveraging AI, Big Data, and digital sensors; continued product and service enhancements including LabX software and predictive maintenance tools.
Service growth driver: Services account for ~25% of sales, supported by iBase penetration, AI-driven analytics, upsell campaigns, and remote diagnostics to maximize customer uptime.
Strong financial track record: FY 2024 net sales $3,872 M (+2% USD, +3% local), gross margin 61%, adjusted operating margin 31%, adjusted operating profit $1,200 M, adjusted EPS $41.11.

1 day ago

Presentation

Mettler-Toledo previews FY2026 outlook at Citi Annual Global Healthcare Conference

MTD

Guidance Update

The industrial segment delivered 10% organic growth in Q3 FY2025, with double-digit gains in the Americas and Europe and the first industrial growth in China in two years.
For FY2026, management expects low- to mid-single-digit growth in both the core industrial and product inspection businesses, with organic growth closer to low single digits, excluding acquisition contributions.
The lab division saw strong bioprocess and process analytics performance—driven by bioproduction and semiconductor ultra-pure water demand—while liquid-handling pipettes are expected to remain below corporate average growth.
Service revenue runs at about $1 billion versus a $3 billion serviceable installed base, and the company aims for above-average service growth through targeted penetration initiatives.
Q4 FY2025 margins face headwinds from 200 bps of tariffs and 70 bps of currency impacts, though tariff mitigation and organizational agility have offset much of the pressure.

Dec 3, 2025, 3:30 PM

Transcript

Mettler-Toledo outlines FY2026 guidance and strategic priorities at Citi Healthcare Conference

MTD

Guidance Update

M&A

FY2026 guidance targets low- to mid-single-digit revenue growth, including ~2.5% pricing, ~1% contribution from recent bolt-on acquisitions and ~1% organic volume growth amid cautiously positioned market assumptions
Bolt-on acquisitions completed in FY2025 are expected to contribute ~100 bps per quarter in FY2026, primarily on the industrial side, enhancing direct distribution, service offerings and expanding the life-science equipment portfolio
Tariff and currency impacts will pressure Q4 2025 gross margins by ~200 bps and operating margins by ~70 bps; mitigation actions limit incremental Swiss tariff effects to <1% EPS upside in FY2026
Market trends: Chinese industrial returned to growth driven by pharmaceuticals, food manufacturing and specialty chemicals; lab segment shows strength in bioprocess analytics and process sensors, with softer liquid handling amid academic funding pressures

Dec 3, 2025, 3:30 PM

Transcript

Mettler-Toledo outlines FY2026 outlook at Evercore HealthCONx

MTD

Guidance Update

Mettler-Toledo highlighted its innovation pedigree—80–120 years across its brands—and holds the global #1 position in 75–80% of its ~25 niche markets with an average ~25% market share, driven by its Spinnaker program and 3,000 direct sales staff.
The company’s revenue split is 55% laboratory, 40% industrial (25% core industrial; 15% product inspection), and 5% food retail, with key offerings spanning balances, analytical instruments, liquid handling, AutoChem synthesis, and bioprocessing analytics.
Average selling price is under $10,000, sold directly to end users, enabling consistent 1–2% pricing increases and rigorous price-leakage management.
For FY2026, Mettler-Toledo guides to low–mid single-digit organic growth, reflecting caution on macro uncertainty, softer European markets, and tougher comparables in product inspection.
Services are expected to grow mid–high single digits, leveraging a $3 billion serviceable install base against a $1 billion installed base, supported by targeted investments in service capabilities.

Dec 2, 2025, 2:10 PM

Transcript

Mettler-Toledo presents strategic update and FY26 guidance

MTD

Guidance Update

Mettler-Toledo emphasizes its innovation-led competitive advantage across ~25 niche product categories, leveraging the Spinnaker operational-excellence program and disciplined pricing (average price <$10k) to drive share gains and margin capture.
The business mix is 55% laboratory products, 40% industrial (25% core, 15% product inspection) and 5% food retail; end-market exposure is 40% pharma/bio-pharma, 20% food manufacturing and 10–15% specialty chemical.
Digitalization efforts include completion of the Blue Ocean ERP/CRM harmonization, deployment of automation bots and generative-AI tools (e.g., ChatMT), plus embedded AI in customer products for predictive analytics (AutoChem).
In 3Q 2025, core industrial grew 10% organically and product inspection high-single digits; 4Q guide steps to low-single digits (core) and high-single digits (PID), with FY 2026 growth expected in the low-to-mid single digits and services in mid-to-high single digits.
China returned to low-single-digit growth in both lab and industrial segments in 3Q after two years, supported by a China-for-China strategy and rising GLP-1 biopharma activity.

Dec 2, 2025, 2:10 PM

Transcript

Mettler-Toledo reports Q3 2025 results

MTD

Earnings

Guidance Update

Q3 sales were $1.03 billion, up 6% in local currency (8% reported), led by 10% growth in the Americas, 6% in Europe, and 1% in Asia.
Gross margin declined 80 bps to 59.2%, adjusted operating profit rose 5% to $309.9 million, with operating margin at 30.1% (down 100 bps); adjusted EPS was $11.15, up 9%.
Adjusted free cash flow for the first nine months was $689.5 million, a 6% increase per share; DSO was 34 days and ITO 4.2×.
Q4 guidance calls for ~3% local-currency sales growth and adjusted EPS of $12.68–$12.88 (2–4% growth); full-year 2025 EPS forecast is $42.05–$42.25 (2–3% growth).

Nov 7, 2025, 1:30 PM

Transcript

Mettler-Toledo reports Q3 2025 results

MTD

Earnings

Guidance Update

M&A

$1.03 billion in Q3 sales, up 6% in local currency (8% in USD); excluding recent acquisitions, sales increased 5% versus prior year.
Segment growth: laboratory sales +4%, industrial +9% (10% core ex-acquisitions), product inspection +7%, service +8% (1% acquisition benefit).
Gross margin of 59.2% (down 80 bps); adjusted operating margin 30.1% (down 100 bps; 30 bps currency-neutral); tariffs reduced operating margin by 140 bps.
Adjusted EPS of $11.15, a 9% increase year-over-year; reported EPS $10.57 vs. $9.96 in Q3 2024.
2026 outlook: forecasting ~4% sales growth, expecting to fully offset incremental tariff costs; recent small acquisitions to add <1% to 2026 sales.

Nov 7, 2025, 1:30 PM

Transcript

Earnings Transcripts

Quarterly earnings call transcripts for METTLER TOLEDO INTERNATIONAL INC/.

Q3 2025

Nov 7, 2025

→

Q2 2025

Aug 1, 2025

→

Q1 2025

May 2, 2025

→

View All Transcripts

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Patrick Kaltenbach say about margins?What are METTLER TOLEDO INTERNATIONAL INC/'s strategic priorities?How is METTLER TOLEDO INTERNATIONAL INC/ positioned vs competitors?How did METTLER TOLEDO INTERNATIONAL INC/ do last quarter?

METTLER TOLEDO INTERNATIONAL INC/ (MTD)

Analyst Earnings Quarterly Reports

Q3 2025

Q2 2025

Q1 2025

Q4 2024

Executives

Patrick Kaltenbach

Gerhard Keller

Marc de La Guéronnière

Richard Wong

Shawn Vadala

Board Members

Brian Shepherd

Domitille Doat-Le Bigot

Elisha Finney

Ingrid Zhang

Michael Kelly

Pablo Perversi

Roland Diggelmann

Thomas Salice

Wolfgang Wienand

Analyst Coverage

Joshua Waldman

Michael Ryskin

Patrick Donnelly

Vijay Kumar

Daniel Arias

Jack Meehan

Tycho Peterson

Brandon Couillard

Casey Woodring

Doug Schenkel

Luke Sergott

Matthew Sykes

Rachel Vatnsdal Olson

Dan Arias

Daniel Leonard

Jack Slevin

Josh Heinen

Catherine Ramsey

Catherine Schulte

Dan Leonard

Douglas Schenkel

Latest news

Earnings Transcripts

Q3 2025

Q2 2025

Q1 2025

Ask Fintool AI Agent